Category Archives: The Viewpoint

Ops Page for Editorials, and …Opinions

Ensitrelvir for Covid Prevention: This Emperor Has No Clothes

Posted on by — No Comments ↓

Just imagine you were tasked to conduct a seasonal flu study in household contacts of a symptomatic index case.  Your intervention may be (your choice): pre-season vaccination, pre-exposure prophylaxis, or some non-anti-infective protective measure such as wearing a face mask, taking a vitamin or analgesic that is believed to confer Continue reading Ensitrelvir for Covid Prevention: This Emperor Has No Clothes→

OFF-TARGET ANTIBODIES

Posted on by — No Comments ↓

Quick: What do you associate with the abbreviation ‘TCR’?  Does your immunology-trained mind automatically default to ‘T-cell receptor’?  Or is your first guess ‘Tissue Cross Reactivity?  Our neural networks can deal with ambivalence and will make the right associations, eventually.  Language is imprecise by design and allows for wobble. Things Continue reading OFF-TARGET ANTIBODIES→

The Tiragolumab Saga & Tifacogin Flash-Backs

Posted on by — No Comments ↓

A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1]  The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs→